I work at amgen. ask me anthing. I'll answer honestly

Quote






anonymous said:
OP back again. Closing date is expected mid March.
Click to expand...


Well, if your source is the same one that didn’t know that the original transaction agreement stated that we keep our bases & target IC bonus dollar amount, we won’t hold our breaths that their expectations mean anything. Stop trying to act like you know anything beyond what the rest of us know.
 












anonymous said:
Per the email sent at Amgen yesterday, what’s the word in Kave & what does GCO stand for?
Click to expand...


Kave is the best GM we had. He has fought the Amgen culture of teleconferences, QBRs and FCRs his whole time. You are lucky to get him.

The real worry now for inflam, is do we return to the days of 4DX, week long meetings, 3 district calls per week, and entering calls on everyone regardless of whether they are an HCP or not?

I wish he could have done a bit more to infuse us with dermatology's ethos before he left, but at least he tried.

GCO is Global Commercial Operations
 






anonymous said:
Kave is the best GM we had. He has fought the Amgen culture of teleconferences, QBRs and FCRs his whole time. You are lucky to get him.

The real worry now for inflam, is do we return to the days of 4DX, week long meetings, 3 district calls per week, and entering calls on everyone regardless of whether they are an HCP or not?

I wish he could have done a bit more to infuse us with dermatology's ethos before he left, but at least he tried.

GCO is Global Commercial Operations
Click to expand...

thanks! So that email was confusing, then. Is he just moving over to an operations role which includes leading the integration, or will there be a new BU for Horizon/rare disease? It says there will be only 3 BUs now, but then at the bottom it says the USBO business units will be led by the following…and then there’s 4 leads…but it just referenced leading the Horizon integration & doesn’t reference a new BU. Not sure how things are structured there with your ops.
 






anonymous said:
thanks! So that email was confusing, then. Is he just moving over to an operations role which includes leading the integration, or will there be a new BU for Horizon/rare disease? It says there will be only 3 BUs now, but then at the bottom it says the USBO business units will be led by the following…and then there’s 4 leads…but it just referenced leading the Horizon integration & doesn’t reference a new BU. Not sure how things are structured there with your ops.
Click to expand...


Currently 3 BUs and when the integration is complete, there will be a 4th, Rare Disease, headed by Kave and his lieutenants. Some of you will be in Rare Disease while others, like your gout team, will be digested by Inflammation.
 












anonymous said:
Currently 3 BUs and when the integration is complete, there will be a 4th, Rare Disease, headed by Kave and his lieutenants. Some of you will be in Rare Disease while others, like your gout team, will be digested by Inflammation.
Click to expand...

Gout team is headed to rare disease- the question is how many will be heading over and how many will be let go. Still being discussed.
 
























anonymous said:
ya know what's really rare?

The number of people who think Gout is a rare disease. They all seem to work at Horizon, at least for now.
Click to expand...

Oh, nice! The idiot who thinks they know more than the rest of the world, including the FDA is back. We get it, you dude agree with the FDAs decision of what is an orphan disease and/or disagree with ALL of the data on the population with uncontrolled chronic gout. You probably think that COVID was a farce, too. Now move on.
 


















anonymous said:
Gout team is headed to rare disease- the question is how many will be heading over and how many will be let go. Still being discussed.
Click to expand...

Well, it would be weird if it wasn’t being discussed. It would be weird if there wasn’t a discussion about every role. Lol!
The primary growth driver as of late has been from the Nephrology team. That being said, the way we are organized as separate from rheum and the way we are and are going to start being paid is so stupid, Amgen just needs to shrink the territories a bit & have one rep that calls on all specialties within the geography. Keep it simple.
 






anonymous said:
Well, it would be weird if it wasn’t being discussed. It would be weird if there wasn’t a discussion about every role. Lol!
The primary growth driver as of late has been from the Nephrology team. That being said, the way we are organized as separate from rheum and the way we are and are going to start being paid is so stupid, Amgen just needs to shrink the territories a bit & have one rep that calls on all specialties within the geography. Keep it simple.
Click to expand...

Thats not really true. A large percentage of 'nephrology" scripts are because the rheum rep is being nice and adding you on a PEF. Very little infusions are happening in Nephrology and very few true referrals are being generated. Everyone knows this including management. Talked about on pretty much every leadership call.

Not that nephrology doesn't have a place. But not really sure if that expansion was necessary or paying any ROI.
 






anonymous said:
Thats not really true. A large percentage of 'nephrology" scripts are because the rheum rep is being nice and adding you on a PEF. Very little infusions are happening in Nephrology and very few true referrals are being generated. Everyone knows this including management. Talked about on pretty much every leadership call.

Not that nephrology doesn't have a place. But not really sure if that expansion was necessary or paying any ROI.
Click to expand...

Well, I thought the same thing because I know an NSAM that plays that game, but our neph report that we get emailed daily shows if it is a joint start (lists rheum & neph if it’s a referral), I think it was 70-75% of them are neph only. I would have to go back and check the exact number. Not that I have had a ton of starts, but all but one were neph only treating. Plus, I have very little doubt that there are plenty of referrals that neph doesn’t get credit for due to rheum not filling out a PEF or bothering to add the name.
I totally agree, though, that the expansion was completely unnecessary. The whole set up is just strange.
Well, maybe Amgen will straighten it out. Who in the hell knows?
 






anonymous said:
Well, I thought the same thing because I know an NSAM that plays that game, but our neph report that we get emailed daily shows if it is a joint start (lists rheum & neph if it’s a referral), I think it was 70-75% of them are neph only. I would have to go back and check the exact number. Not that I have had a ton of starts, but all but one were neph only treating. Plus, I have very little doubt that there are plenty of referrals that neph doesn’t get credit for due to rheum not filling out a PEF or bothering to add the name.
I totally agree, though, that the expansion was completely unnecessary. The whole set up is just strange.
Well, maybe Amgen will straighten it out. Who in the hell knows?
Click to expand...

But many nephrologist don't treat refractory gout because its under control from dialysis. Their words not mine. We do have some areas where nephrologist are treating but its the exception not the rule.
 






anonymous said:
Well, I thought the same thing because I know an NSAM that plays that game, but our neph report that we get emailed daily shows if it is a joint start (lists rheum & neph if it’s a referral), I think it was 70-75% of them are neph only. I would have to go back and check the exact number. Not that I have had a ton of starts, but all but one were neph only treating. Plus, I have very little doubt that there are plenty of referrals that neph doesn’t get credit for due to rheum not filling out a PEF or bothering to add the name.
I totally agree, though, that the expansion was completely unnecessary. The whole set up is just strange.
Well, maybe Amgen will straighten it out. Who in the hell knows?
Click to expand...

The vast majority of our vials are without a PEF. And as someone who has been here for 6 years its mainly from Rheumatologist.
 






anonymous said:
The vast majority of our vials are without a PEF. And as someone who has been here for 6 years its mainly from Rheumatologist.
Click to expand...


That is not true that nationally the majority of vials don’t have a PEF. It’s pretty easy to break out with data entered into PARC by PALs (number of infusions) vs vials, but there are plenty that don’t get them…yet again, there are undoubtedly some that are neph referrals, too, for which they get zero credit.
Also, the comment was about were the growth has come from, not overall business,
On a side note, it's beyond pathetic that more vials aren’t accompanied by PEFs. God only knows how many patients either pay more than they need to or don’t get on therapy because an infusion center tells them what their copay is and they back out. It is a thousand times easier here than when I sold an injectable drug to rheum. One of the SAMs on my team is just lazy AF. A little less than half of his PEFs have vials, and it’s from the same few providers who are easy to access but far away from his house. He has the lowest percentage PEFs by far and away on our team. It’s pretty sad because in those far away rural areas there are a lot of people that could use the financial help.
 






Top Bottom
Back
Quote